Prospective Grant of an Exclusive Patent License: Thio Compounds and Thalidomide Analogues for the Treatment of Neurological Diseases, 22743 [2020-08560]
Download as PDF
<![CDATA[
Federal Register / Vol. 85, No. 79 / Thursday, April 23, 2020 / Notices
• PreF and preF–HN immunogens are
stable for over a month at 37 °C, the
lyophilized product may be stable at
room temperature for months.
• Recombinant vaccine production is
scalable, cost-effective vaccine
production can be achieved.
Development Stage: Preclinical
Research.
Inventors: Barney Graham, Ph.D.
(NIAID); Guillaume Stewart-Jones, Ph.D.
(NIAID).
Intellectual Property: HHS Reference
Number E–153–2019 includes U.S.
Provisional Patent Application Number
62/946,902 filed 12/11/2019.
Licensing Contact: To license this
technology, please contact Amy F.
Petrik, Ph.D., 240–627–3721;
amy.petrik@nih.gov.
Dated: April 12, 2020.
Wade W. Green,
Acting Deputy Director, Technology Transfer
and Intellectual Property Office, National
Institute of Allergy and Infectious Diseases.
[FR Doc. 2020–08561 Filed 4–22–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Thio Compounds and
Thalidomide Analogues for the
Treatment of Neurological Diseases
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Institute on
Aging and the National Cancer Institute,
institutes of the National Institutes of
Health, Department of Health and
Human Services, are contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
U.S. and foreign Patents and Patent
Applications listed in the
Supplementary Information section of
this notice to AevisBio, Inc. located in
814 W Diamond Ave., Suite 203,
Gaithersburg, MD 20870.
DATES: Only written comments and/or
applications for a license which are
received by the National Institute on
Aging c/o National Cancer Institute’s
Technology Transfer Center on or before
May 8, 2020 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
Exclusive Patent License should be
directed to: Merissa Baxter, Ph.D.,
Technology Transfer Manager, NCI
Technology Transfer Center, 9609
lotter on DSKBCFDHB2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
19:28 Apr 22, 2020
Jkt 250001
Medical Center Drive, Rm. 1E406 MSC
9702, Bethesda, MD 20892–9702 (for
business mail), Rockville, MD 20850–
9702, Telephone: 240–276–7234, Email:
merissa.baxter@nih.gov.
SUPPLEMENTARY INFORMATION:
Intellectually Property
United States Patent No. 8,927,725,
issued January 6, 2015 and entitled
‘‘Thio Compounds’’ [HHS Reference No.
E–045–2012–0–US–01]; United States
Patent No. 9,084,783, issued July 21,
2015 and entitled ‘‘Thio
Compounds’’[HHS Reference No. E–
045–2012–0–US–02]; United States
Patent No. 9,623,020, issued April 18,
2017 and entitled ‘‘Thio Compounds’’
[HHS Reference No. E–045–2012–0–
US–03]; United States Patent No.
10,220,028, issued March 5, 2019 and
entitled ‘‘Thio Compounds’’ [HHS
Reference No. E–045–2012–0–US–04];
US Provisional Patent Application No.
62/235,105, filed on September 30, 2015
and entitled ‘‘Thalidomide Analogs and
Methods of Use’’ [HHS Reference No. E–
208–2015–0–US–01]; PCT Patent
Application No. PCT/US2016/054430,
filed on September 29, 2016 and
entitled, ‘‘Thalidomide Analogs and
Methods of Use’’ [HHS Reference No. E–
208–2015–0–PCT–02]; Australian Patent
Application No. 2016330967, filed on
September 29, 2016 and entitled
‘‘Thalidomide Analogs and Methods of
Use’’ [HHS Reference No. E–208–2015–
0–AU–03]; Canadian Patent Application
No. 3000661, filed on September 29,
2019 and entitled ‘‘Thalidomide
Analogs and Methods of Use’’ [HHS
Reference No. E–208–2015–0–CA–04];
European Patent Application No.
16782148.7, filed on September 29,
2019 and entitled ‘‘Thalidomide
Analogs and Methods of Use’’ [HHS
Reference No. E–208–2015–0–EP–05];
South Korean Patent Application No.
10–2018–7012347, filed on April 13,
2018 and entitled ‘‘Thalidomide
Analogs and Methods of Use’’ [HHS
Reference No. E–208–2015–0–KR–06];
and United States Patent Application
No. 15/764,193, filed on March 28, 2018
and entitled ‘‘Thalidomide Analogs and
Methods of Use’’ [HHS Reference No. E–
208–2015–US–07].
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be world-wide, and the
field of use may be limited to the use
of Licensed Patent Rights for the
following: ‘‘The development,
production, and commercialization of a
select subset of thalidomide/
lenalidomide/pomalidomide (POMA)
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
22743
analogue compounds for the therapeutic
treatment of neurological disorders
prevalent in aging: Specifically,
Traumatic Brain Injury (TBI),
Alzheimer’s disease (AD), Parkinson’s
disease (PD), and Multiple Sclerosis
(MS).’’
These technologies disclose novel
thalidomide, lenalidomide, and
pomalidomide analogues that can
potentially be used for the treatment of
neurological diseases, autoimmunity,
and/or cancer.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Institute on Aging receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: April 13, 2020.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2020–08560 Filed 4–22–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[Docket ID FEMA–2020–0002; Internal
Agency Docket No. FEMA–B–2014]
Proposed Flood Hazard
Determinations
Federal Emergency
Management Agency; DHS.
ACTION: Notice; correction.
AGENCY:
On March 13, 2020, FEMA
published in the Federal Register a
proposed flood hazard determination
notice that contained an erroneous
SUMMARY:
E:\FR\FM\23APN1.SGM
23APN1
]]>Agencies
[Federal Register Volume 85, Number 79 (Thursday, April 23, 2020)]
[Notices]
[Page 22743]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-08560]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Thio Compounds
and Thalidomide Analogues for the Treatment of Neurological Diseases
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute on Aging and the National Cancer
Institute, institutes of the National Institutes of Health, Department
of Health and Human Services, are contemplating the grant of an
Exclusive Patent License to practice the inventions embodied in the
U.S. and foreign Patents and Patent Applications listed in the
Supplementary Information section of this notice to AevisBio, Inc.
located in 814 W Diamond Ave., Suite 203, Gaithersburg, MD 20870.
DATES: Only written comments and/or applications for a license which
are received by the National Institute on Aging c/o National Cancer
Institute's Technology Transfer Center on or before May 8, 2020 will be
considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated Exclusive Patent License
should be directed to: Merissa Baxter, Ph.D., Technology Transfer
Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, Rm.
1E406 MSC 9702, Bethesda, MD 20892-9702 (for business mail), Rockville,
MD 20850-9702, Telephone: 240-276-7234, Email: [email protected].
SUPPLEMENTARY INFORMATION:
Intellectually Property
United States Patent No. 8,927,725, issued January 6, 2015 and
entitled ``Thio Compounds'' [HHS Reference No. E-045-2012-0-US-01];
United States Patent No. 9,084,783, issued July 21, 2015 and entitled
``Thio Compounds''[HHS Reference No. E-045-2012-0-US-02]; United States
Patent No. 9,623,020, issued April 18, 2017 and entitled ``Thio
Compounds'' [HHS Reference No. E-045-2012-0- US-03]; United States
Patent No. 10,220,028, issued March 5, 2019 and entitled ``Thio
Compounds'' [HHS Reference No. E-045-2012-0-US-04]; US Provisional
Patent Application No. 62/235,105, filed on September 30, 2015 and
entitled ``Thalidomide Analogs and Methods of Use'' [HHS Reference No.
E-208-2015-0-US-01]; PCT Patent Application No. PCT/US2016/054430,
filed on September 29, 2016 and entitled, ``Thalidomide Analogs and
Methods of Use'' [HHS Reference No. E-208-2015-0-PCT-02]; Australian
Patent Application No. 2016330967, filed on September 29, 2016 and
entitled ``Thalidomide Analogs and Methods of Use'' [HHS Reference No.
E-208-2015-0-AU-03]; Canadian Patent Application No. 3000661, filed on
September 29, 2019 and entitled ``Thalidomide Analogs and Methods of
Use'' [HHS Reference No. E-208-2015-0-CA-04]; European Patent
Application No. 16782148.7, filed on September 29, 2019 and entitled
``Thalidomide Analogs and Methods of Use'' [HHS Reference No. E-208-
2015-0-EP-05]; South Korean Patent Application No. 10-2018-7012347,
filed on April 13, 2018 and entitled ``Thalidomide Analogs and Methods
of Use'' [HHS Reference No. E-208-2015-0-KR-06]; and United States
Patent Application No. 15/764,193, filed on March 28, 2018 and entitled
``Thalidomide Analogs and Methods of Use'' [HHS Reference No. E-208-
2015-US-07].
The patent rights in these inventions have been assigned and/or
exclusively licensed to the government of the United States of America.
The prospective exclusive license territory may be world-wide, and
the field of use may be limited to the use of Licensed Patent Rights
for the following: ``The development, production, and commercialization
of a select subset of thalidomide/lenalidomide/pomalidomide (POMA)
analogue compounds for the therapeutic treatment of neurological
disorders prevalent in aging: Specifically, Traumatic Brain Injury
(TBI), Alzheimer's disease (AD), Parkinson's disease (PD), and Multiple
Sclerosis (MS).''
These technologies disclose novel thalidomide, lenalidomide, and
pomalidomide analogues that can potentially be used for the treatment
of neurological diseases, autoimmunity, and/or cancer.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the National
Institute on Aging receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information in these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: April 13, 2020.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2020-08560 Filed 4-22-20; 8:45 am]
BILLING CODE 4140-01-P
